LyGenesis and Imagine Pharma to jointly develop cell therapies for Patients with Type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
To enable company to be future-ready by tapping potential in CDMO space
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Bourgoin early development hub broadens offerings for oral solid dose formulations
The C20 is an engagement group of the G20 that focuses on Civil issues and looks to promote sustainable growth and financial stability.
Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated